J.P. Morgan analyst Jessica Fye maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00.

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

Invest in the best value stocks with Interactive Brokers for quick trade execution. Value stocks/companies consist of companies whose current valuation appears low relative to their fundamentals ...